Diffuse large B-cell lymphoma activated B-cell type
MONDO:0850418A diffuse large B-cell lymphoma that is characterized by the expression of CD44, PKCbeta1, Cyclin D2, BCL-2, and IRF4/MUM1 genes.
2000 clinical trials for this condition and its sub-types, 9 tagged with Diffuse large B-cell lymphoma activated B-cell type itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New drug tegavivint takes on tough lymphoma in early trial
Disease control Recruiting nowThis early-phase trial is testing a drug called tegavivint in about 18 people with large B-cell lymphoma that has come back or not responded to standard treatments. The drug works by blocking certain enzymes that help cancer cells grow. The main goals are to find a safe dose and …
Phase 1 • Sponsor: Lapo Alinari • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo therapy aims to boost CAR t-cell success in hard-to-treat blood cancers
Disease control Recruiting nowThis early-phase study tests a radioactive drug (131-I apamistamab) given before CAR T-cell therapy for people with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma. The goal is to find a safe dose and see if the combination is tolera…
Early phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New combo may help more lymphoma patients reach potentially curative CAR-T
Disease control Recruiting nowThis study tests whether giving two drugs, golcadomide and rituximab, before CAR-T cell therapy can help control aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to prior treatment. The goal is to keep the disease in check so more patients can qualify for…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC